Loading company…
Pulmocide develops inhaled antifungal treatments for serious lung diseases, led by opelconazole for invasive pulmonary aspergillosis.
Founded in 2013 and based in London, UK, Pulmocide Limited is developing opelconazole, an inhaled antifungal designed to deliver high drug concentrations to the lungs, which is in Phase 3 clinical trials. In December 2022 the company raised USD 52.00 mn in Series C funding, co-led by Pictet Alternative Advisors and Vivo Capital, with investors including Adjuvant Capital and Johnson & Johnson Innovation. It has completed 6 deals.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in